GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Itacitinib (Primary) ; Ciclosporin; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms GRAVITAS-119
- Sponsors Incyte Corporation
- 10 Oct 2019 Planned number of patients changed from 60 to 85.
- 10 Oct 2019 Planned End Date changed from 1 Jan 2021 to 1 Jul 2021.
- 10 Oct 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Jul 2020.